# QIC BioVentures

> QIC BioVentures is a VC fund in Brisbane backing Medical and Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Brisbane, Australia
- Total investments: 3
- Last investment: Apr 2011
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.qbf.qic.com

QIC BioVentures is a VC fund in Brisbane focused on Medical and Health Care. QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.

## Contacts

5 contacts available for QIC BioVentures. Shizune tracks 5 team members at QIC BioVentures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/qic-bioventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adriaan Ryder | Chief Investment Officer | 0 | https://shizune.co/investors/profile/adriaan-ryder |
| David Usasz | Non-Executive Director | 0 | https://shizune.co/investors/profile/david-usasz |
| Grant Murdoch | Non-Executive Director | 0 | https://shizune.co/investors/profile/grant-murdoch |
| Maurice L Newman | Non-Executive Director | 0 | https://shizune.co/investors/profile/maurice-l-newman |
| Paul Leitch | Chief Operating Officer | 0 | https://shizune.co/investors/profile/paul-leitch |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Verva Pharmaceuticals | Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy. | $1.4M |  | Apr 29, 2011 |  |
| Verva Pharmaceuticals | Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy. | $1M |  | Jun 18, 2009 |  |
| Protagonist Therapeutics | Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. | $9M | Series A | Sep 19, 2006 |  |

3 of 3 investments shown.

## Co-investors
- [GBS Ventures](https://shizune.co/investors/profile/gbs-ventures) — VC Fund, 2 deals together
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 2 deals together
- [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures) — VC Fund, 1 deal together
- [Starfish Ventures](https://shizune.co/investors/profile/starfish-ventures) — VC Fund, 1 deal together
- [Westscheme Pty Limited](https://shizune.co/investors/profile/westscheme-pty-limited) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Biotechnology Investors in Australia](https://shizune.co/investors/biotechnology-investors-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)
- [Health Care Investors in Australia](https://shizune.co/investors/health-care-investors-australia)
- [Health Care VC Funds in Australia](https://shizune.co/investors/health-care-vc-funds-australia)

## FAQ

### What does QIC BioVentures invest in?

QIC BioVentures invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact QIC BioVentures?

Public channels for QIC BioVentures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at QIC BioVentures?

The team at QIC BioVentures includes Adriaan Ryder (Chief Investment Officer), David Usasz (Non-Executive Director) and Grant Murdoch (Non-Executive Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co